Fate Therapeutics, Inc.

NasdaqGM:FATE Voorraadrapport

Marktkapitalisatie: US$326.4m

Fate Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Fate Therapeutics is Bob Valamehr, benoemd in Jan2025, heeft een ambtstermijn van 1.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.25M, bestaande uit 26.7% salaris en 73.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 408.41K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 7.1 jaar.

Belangrijke informatie

Bob Valamehr

Algemeen directeur

US$2.2m

Totale compensatie

Percentage CEO-salaris26.68%
Dienstverband CEO1.6yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn1.6yrs
Gemiddelde ambtstermijn bestuur7.1yrs

Recente managementupdates

Recent updates

Seeking Alpha • Jun 24

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Summary Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on FT819 for lupus nephritis. I believe FT819 has made good progress since the last time I covered the stock. They’ve reported broader autoimmune data and are now planning RECLAIM-LN. Unfortunately, I think their recent removal from the Russell 3000 index could be a near-term headwind for the stock price itself. However, I don’t think this index removal will have a major impact on their underlying R&D progress with FT819. On balance, I still believe FATE offers good upside potential at these levels despite its inherent risks tied to RECLAIM-LN’s clinical data in the long run. Read the full article on Seeking Alpha
Analyse-artikel • Nov 25

Here's Why We're A Bit Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analyse-artikel • Aug 08

Here's Why We're Watching Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

NasdaqGM:FATE 1 Year Share Price vs Fair Value Explore Fate Therapeutics's Fair Values from the Community and select...
Analyse-artikel • Apr 22

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 05

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Summary Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient. Valuation-wise, I think FATE’s low P/B relative to peers shows it is cheap, even though that’s partially due to its early-stage pipeline. The main risk I see with FATE is its inherently speculative R&D progress, but also its cash burn, which could become an issue by 2027. Other than that, I rate FATE a “Buy”. Read the full article on Seeking Alpha
Analyse-artikel • Jan 06

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Nov 20

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Summary Fate Therapeutics, Inc. reported positive phase 1 data for FT819 in treating moderate-to-severe Systemic Lupus Erythematosus, showing remission in one patient with fludarabine-free conditioning. A second study arm will test FT819 as an add-on to maintenance therapy without conditioning chemotherapy targeting SLE patients. Data from the first three patients will be presented at the American Society of Hematology Annual Meeting, being held between December 7th through 10th of 2024. FT522 is also being explored in phase 1 trials for the treatment of patients with relapsed/refractory B-cell lymphoma and B-cell mediated autoimmune disorders. Read the full article on Seeking Alpha
Analyse-artikel • Aug 21

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders will have a reason to smile today, with the analysts making...
Analyse-artikel • Aug 11

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 29

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Summary Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share. Read the full article on Seeking Alpha
Analyse-artikel • Apr 23

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have retraced a considerable 28% in the last month, reversing a fair...
Analyse-artikel • Feb 16

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Despite an already strong run, Fate Therapeutics, Inc. ( NASDAQ:FATE ) shares have been powering on, with a gain of 57...
Seeking Alpha • Jan 26

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Summary Fate Therapeutics is a cell therapy-focused biotech that is overvalued and should be sold due to the risk of value erosion in 2024. The company's most advanced pipeline projects are FT576 and FT819, but no updates have been provided since the last article. The transition of their HER2-targeted CAR T-cell product, FT825, into phase 1 study is a significant development, but early data is needed to determine its potential. Read the full article on Seeking Alpha
Analyse-artikel • Dec 19

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

The Fate Therapeutics, Inc. ( NASDAQ:FATE ) share price has done very well over the last month, posting an excellent...
Analyse-artikel • Sep 08

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyse-artikel • Jun 07

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4x Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be sending very bullish...
Analyse-artikel • May 08

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Shareholders in Fate Therapeutics, Inc. ( NASDAQ:FATE ) may be thrilled to learn that the analysts have just delivered...
Analyse-artikel • Apr 17

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyse-artikel • Jan 10

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyse CEO-vergoeding

Hoe is Bob Valamehr's beloning veranderd ten opzichte van Fate Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2026n/an/a

-US$130m

Dec 31 2025US$2mUS$600k

-US$136m

Sep 30 2025n/an/a

-US$156m

Jun 30 2025n/an/a

-US$172m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$4mUS$525k

-US$186m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$3mUS$500k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$3mUS$455k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$6mUS$430k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$2mUS$390k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$3mUS$375k

-US$98m

Compensatie versus markt: De totale vergoeding ($USD 2.25M ) Bob } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Bob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bob Valamehr (49 yo)

1.6yrs
Tenure
US$2,248,568
Compensatie

Dr. Bahram Valamehr, also known as Bob, Ph D, M.B.A., is President and CEO of Fate Therapeutics, Inc. since January 01, 2025 and serves as its Director since January 2025 and was its President of Research...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Bahram Valamehr
President1.6yrsUS$2.25m0.13%
$ 408.4k
Kamal Adawi
CFO & Treasurerless than a yearUS$1.11m0%
$ 0
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary10.8yrsUS$1.11m0.51%
$ 1.7m
Jessica Francis
Senior Vice President of Human Resources & Operations1.6yrsgeen gegevensgeen gegevens
Martin Hosking
Head of Researchless than a yeargeen gegevensgeen gegevens
Tunde Babalola
Senior Vice President of Technical Operations & Quality1.6yrsgeen gegevensgeen gegevens
Ryan Douglas
Senior Director of Investor Relations & Business Developmentless than a yeargeen gegevensgeen gegevens
Andrew Henry
Senior Vice President of Clinical Operations2.6yrsgeen gegevensgeen gegevens
Yu Cai
Head of Intellectual Property & Assistant General Counsel1.6yrsgeen gegevensgeen gegevens
Kate Duvall
Corporate Controller1.3yrsgeen gegevensgeen gegevens
1.6yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van FATE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Bahram Valamehr
President1.6yrsUS$2.25m0.13%
$ 408.4k
William Rastetter
Independent Chairman14.8yrsUS$142.98k0.55%
$ 1.8m
Robert Epstein
Independent Director12.4yrsUS$123.71k0.031%
$ 101.7k
Michael Lee
Independent Director8.1yrsUS$104.09k0.0097%
$ 31.7k
Laura Hamill
Independent Directorless than a yeargeen gegevensgeen gegevens
Matthew Abernethy
Independent Director1.3yrsUS$151.61k0%
$ 0
Karin Jooss
Independent Director7.4yrsUS$118.96k0.0084%
$ 27.6k
Shefali Agarwal
Independent Director7.1yrsUS$115.09k0.0090%
$ 29.4k
Yuan Xu
Independent Director5yrsUS$111.52k0.0074%
$ 24.3k
7.1yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FATE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/08/10 20:42
Aandelenkoers aan het einde van de dag2026/08/10 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Fate Therapeutics, Inc. wordt gevolgd door 25 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Jack AllenBaird
Tazeen AhmadBofA Global Research
Amanda MurphyBTIG